Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNM005 in healthy volunteers
NCT06068608Phase 1Recruiting
- Sponsor
- Trinomab Pharmaceutical
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TNM005 in varicella (VZV) (6 arms), sponsored by Trinomab Pharmaceutical. Primary endpoints: Incidence of AEs, Number of participants Physical examinations abnormalities and 3 more. Started Sep 2023; status: recruiting.
02
Drugs
TNM005
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT06068608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06068608.